Mechanisms
Lp(a) is procoagulant, not antifibrinolytic, in whole particle form, mechanistic clot study (J Thromb Haemost 2026)
Original title: Lipoprotein(a) prolongs ex vivo plasma clot lysis times through effects on clot formation rate and fibrin structure
Mechanistic ex vivo plasma clot study examining Lp(a), apo(a) and apo(a) variants for effects on clot formation, lysis, thrombin generation, plasminogen activation and fibrin architecture, alongside protein modelling of the apo(a)-plasminogen interaction. Isolated apo(a) strongly inhibited fibrinolysis via its protease domain, mediated by Lys216, but modelling suggested this lysine-binding site is blocked from plasminogen within the intact Lp(a) particle by the apoB-containing lipoprotein. Lp(a) and apo(a) shortened plasma clot formation time, and after accounting for this, Lp(a) showed a small but significant prolongation of fibrinolysis; procoagulant effects involved lysis-resistant clot architecture and were mediated through the strong lysine-binding site in apo(a) kringle IV type 10, and Lp(a) (but not apo(a) alone) accelerated thrombin generation. The authors conclude apo(a)'s strong antifibrinolytic effect is not retained in the whole Lp(a) particle, which instead shows procoagulant effects whose in vivo relevance to thrombosis warrants further study.
Original abstract
Background: Elevated levels of lipoprotein(a) (Lp[a]) are a causal risk factor for atherosclerotic cardiovascular disease. Similarities between the apolipoprotein(a) (apo[a]) component of Lp(a) and plasminogen suggest that antifibrinolytic properties may account for the pathological effects of Lp(a). However, the antifibrinolytic effects of apo(a) do not appear to be retained by the complete Lp(a) particle.
Objectives: We evaluated the effects of Lp(a), apo(a), and various apo(a) variants on clot formation and lysis times, thrombin generation, plasminogen activation, and fibrin architectures in ex vivo plasma clots. We also constructed predictive protein models to gain insight into the apo(a)-plasminogen interaction.
Results: Apo(a) strongly inhibited fibrinolysis, an effect dependent on the presence of the apo(a) protease domain and mediated by Lys216 in this domain. Modeling of apo(a) suggests that Lys216 is blocked from binding to plasminogen in the Lp(a) particle by the presence of the apoB-containing lipoprotein. Lp(a) and apo(a) shortened plasma clot formation times, and accounting for this revealed a small but significant prolongation of fibrinolysis by Lp(a). The procoagulant effects involved the development of lysis-resistant clot architectures and were mediated through the strong lysine-binding site in apo(a) kringle IV type 10. In addition, Lp(a) (but not apo[a]) accelerated thrombin generation.
Conclusions: The strong antifibrinolytic effects of apo(a) do not appear to be retained in the complete Lp(a) particle. However, Lp(a) and apo(a) displayed procoagulant effects, in part dependent on the kringle 4-like lysine-binding site. Further analysis is required to determine whether these reported procoagulant effects of Lp(a) impact thrombosis in vivo.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 17 August 2026. Methods.